top of page

Project partners

There are 5 academic partners and 3 SME partners and 7 associated partners in the CHANGE project, each with unique expertise to add to the collective knowledge and research activities, and together offering 12 DC placements (fully funded full-time PhD projects with multidisciplinary and multi-centre training). 


One of the oldest and most famous Italian universities. The research groups at the Department of Molecular Medicine have a long standing interest in the biochemical characterization of patients with cartilage and bone disorders and in particular in the generation and characterization at the morphological, histological and molecular level of animal models of genetic skeletal diseases in order to elucidate the molecular basis of the disorders and to identify innovative therapeutic approaches. More..


The second-oldest university in Italy and the world's fifth-oldest surviving university. The CHANGE research team at the Medical School has a strong background in cell biology and functional genomics, with a long-lasting interest in extracellular matrix and its role in development and disease. Their research work focuses on the neuromuscular field, including the mechanisms of autophagy in normal and diseased skeletal muscle and the role of matrix components in peripheral and central nervous system. More..


Founded in 1914 with private funding and inspired by the legacy of the European Enlightenment, Goethe University stands out as a pioneering “citizens’ university”. The Medical Faculty has 4 running Collaborative Research Centers, 2 Clusters of Excellence and many more scientific networks. All students enrolled at the GU have full access to GRADE – The Goethe Research Academy for Early Career Researchers. The CHANGE team at  performs cutting-edge basic and clinical research in the field of orthopaedics. More..


Established in 2007 as Scientific cooperation foundation, IMAGINE was awarded the French label of excellence “University Hospital Institute” in 2011 by the French Government. IMAGINE obtained also Carnot Institute label in 2020, certifying the high-quality of its collaborative research with industrial partners. The goal of the institute is to integrate research into clinical practice in order to better understand genetic diseases with unmet medical needs, and to propose and validate diagnostic and therapeutic approaches. More..


ENSL is a world-class academic institute of excellence in higher education and research, ranked 5th of the World's best small universities (THE, 2018). Expertise and research are based on strong disciplinary interdisciplinary competence, and national and international cooperation. The research team at the Institut de Génomique Fonctionnelle de Lyon (IGFL) performs integrative, organism-level research at the interfaces of evolution, physiology and development. More...


Evercyte GmbH was founded in 2010 as a spin-off of BOKU University and the Grillari labs. It has expertise in R&D for translational cell based assays. Evercyte provides relevant human cell lines as model systems for cell based assays, as production hosts for extracellular vesicles (EV), as well as for cellular therapy applications. The team at Evercyte are researching EVs as anti-inflamatory, pro-angiogenic, anti-fibrotic and senomorphic factors, and as potential novel drug candidates in connective tissue disorders and ageing.  More..


LifeTec Group holds a prominent position in the field of biomedical R&D, developing state-of-the art R&D platforms, which combine in-vitro, ex-vivo and in-silico technologies. LifeTec Group offers R&D services to the biomedial industry, clinic and academia by employing multidisciplinary expertise for both research and assessment of new medical technologies, devices and therapies, including innovative in silico, in vitro and ex vivo models, mechanical stimulating bioreactor systems and culture chamber solutions. More..


MEDETIA specializes in the identification of small molecule therapeutics specifically for rare LOF (loss of function) diseases. MEDETIA is composed of a multidisciplinary team of biologists, chemists and pharmacologists, conducting phenotypic tests to identify new therapeutic targets and transform the first candidate molecules towards their pharmaceutical development. MEDETIA is specifically interested in applying high content microscopy, drug repurposing and computational design to ciliary pathologies More..

bottom of page